Ribon Therapeutics announced the first patient has been dosed in the Phase Ib/II study of RBN-2397 in combination with the anti-PD-1 checkpoint inhibitor therapy, pembrolizumab, in patients with squamous cell carcinoma of the lung.
[Ribon Therapeutics]
6445212
nan
items
1
apa
0
default
asc
1
173503
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
